Cadherin‐18 and Preeclampsia: A Novel Biomarker With Prognostic Value in the Second Trimester?
Journal of Obstetrics and Gynaecology Research · 2025-12 · 51 (12)
DOI: 10.1111/jog.70159 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Obstetrics and Gynaecology Research, online erschienen am 04.12.2025. Verfasst von Neset Gumusburun und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Istanbul Aydın University Faculty of Medicine, Istanbul, Turkiye. Hauptthemen laut MEDLINE: Pre-Eclampsia, Pregnancy Trimester, Second, Cadherins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 42 Literaturangaben.
Abstract (Originalsprache)
Objective
Preeclampsia is an obstetric complication with morbidity and mortality that occurs after the 20th week of pregnancy. Cadherins, which play a role in trophoblast development and placentation, are blamed for the pathogenesis of this disease and our aim was to investigate the potential of cadherin‐18 level to predict pre‐eclampsia.
Methods
In this retrospective case–control study, serum cadherin‐18 levels in the early second trimester of pregnancy (between 15 and 20 weeks of gestation) were compared between pregnant women who developed preeclampsia within a 1‐year period and healthy pregnant women.
Results
A total of 170 pregnant women were included in the study; 85 of them were diagnosed with preeclampsia and 85 of them constituted the healthy control group. Of the patients diagnosed with preeclampsia, 40 were classified as early‐onset and 45 as late‐onset preeclampsia. The mean age was 30.8 years in the preeclampsia group and 28.7 years in the control group. Serum cadherin‐18 levels were significantly higher in patients with preeclampsia compared to healthy pregnant women. According to Receiver Operating Characteristic curve analysis, the cut‐off value of 1015.9 pg/mL for the diagnosis of preeclampsia had discriminative power with a sensitivity of 57.6% and specificity of 94.1%. In addition, cadherin‐18 levels above 1302.5 pg/mL provided 85.0% sensitivity and 98.5% specificity in predicting early‐onset preeclampsia.
Conclusion
Cadherin‐18 level is associated with preeclampsia and may be used as a potential biomarker in the prediction of this disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Istanbul Aydın University Faculty of Medicine, Istanbul, Turkiye.
- Department of Medical Biochemistry, Ondokuz Mayis University Faculty of Medicine, Samsun, Turkiye.
- Department of Medical Biochemistry, Samsun Training and Research Hospital, Samsun, Turkiye.
- Department of Obstetrics and Gynecology, Samsun University Faculty of Medicine, Samsun, Turkiye.
- Department of Obstetrics and Gynecology, Samsun Training and Research Hospital, Samsun, Turkiye.
ORCID-Profile: Neset Gumusburun, Sebati Sinan Urkmez, Yesim Civil Urkmez, Sakine Merve Aydin, Bahtiyar Ciftci
Zitieren
APA
Gumusburun, N., Urkmez, S. S., Urkmez, Y. C., Aydin, S. M., & Ciftci, B. (2025). Cadherin‐18 and Preeclampsia: A Novel Biomarker With Prognostic Value in the Second Trimester?. Journal of Obstetrics and Gynaecology Research, 51(12). https://doi.org/10.1111/jog.70159
Vancouver
Gumusburun N, Urkmez SS, Urkmez YC, Aydin SM, Ciftci B. Cadherin‐18 and Preeclampsia: A Novel Biomarker With Prognostic Value in the Second Trimester?. Journal of Obstetrics and Gynaecology Research. 2025;51(12). doi:10.1111/jog.70159
BibTeX
@article{Gumusburun2025,
author = {Gumusburun, Neset and Urkmez, Sebati Sinan and Urkmez, Yesim Civil and Aydin, Sakine Merve and Ciftci, Bahtiyar},
title = {Cadherin‐18 and Preeclampsia: A Novel Biomarker With Prognostic Value in the Second Trimester?},
journal = {Journal of Obstetrics and Gynaecology Research},
year = {2025},
volume = {51},
number = {12},
doi = {10.1111/jog.70159}
}
EUVIMED